Clinical trials of PARPi have assessed their efficacy and tolerance as monotherapy in human epidermal growth factor receptor type 2 (HER2)-negative BC patients carrying a germline P/LPV in BRCA (gBRCA). This evidence concerns the gene ERBB2 and breast cancer.